title: Superficial papillary urothelial neoplasms of the bladder (PTA E PT1): correlation of expression of P53, KI-67 and CK20 with histologic grade, recurrence and tumor progression.
abstract: OBJECTIVE
  To investigate the immunohistochemical expressions of p53, ki67, CK20 in superficial papillary urothelial neoplasms of the bladder and correlate them with histological grade, tumor progression and recurrence.
  
  
  METHODS
  We selected samples of 43 patients with superficial transitional cell carcinoma of the bladder. They were divided into two groups, one called Recurrent (R), with 18 individuals, and other Non-Recurrent (NR), with 25. Multi-sampling blocks were prepared. The immunohistochemical technique employed was immunoperoxidase, and the antibodies were: p53: Novocastra (clone DO7) at a dilution of 1/100; Ki67: Spring (clone SP6) at a dilution of 1/100; and CK20: Dako (clone K20 .8) at a dilution of 1/50.
  
  
  RESULTS
  The expression of p53 was observed in 11 cases, six in the Recurrent group and five in the Non-Recurrent, all high-grade tumors (p = 0.0001). The histological progression occurred in six patients (p = 0.0076). Of the 18 Recurrent cases, six showed immunoreactivity for p53 and 12 were negative for this antibody (p = 0.1715). Ki67 was positive in 17 of the 18 cases from the Recurrent group (p = 0.0001) and, from 20 high-grade tumors, 18 showed reaction to this antibody (p = 0.0001). Of the 18 individuals who had recurrence, 13 showed anomalous expression for CK20 (p = 0.0166). In high-grade carcinomas, of the 20 cases, 16 showed anomalous expression for this antibody, while 18 of the 23 patients with low-grade tumors showed normal expression for CK20 (p = 0.0002).
  
  
  CONCLUSIONS
  The p53 showed good correlation with histological progression and histologic grade. Ki67 was strongly associated with recurrence and histological grade, and CK20 was also associated with these variables.
authors.affiliation: Medical Research Institute, Evangelical Faculty of Paraná / EvangelicalUniversity Hospital of Curitiba, Brazil. daniel.ogata@gmail.com
authors.forename: Daniel Cury
authors.initials: DC
authors.lastname: Ogata
authors.forename: Carmen Austrália Paredes Ribas
authors.initials: CA
authors.lastname: Marcondes
authors.forename: Felipe Francisco
authors.initials: FF
authors.lastname: Tuon
authors.forename: Wilson Francisco Schreiner
authors.initials: WF
authors.lastname: Busato
authors.forename: Gabriela
authors.initials: G
authors.lastname: Cavalli
authors.forename: Letícia Elizabeth Augustin
authors.initials: LE
authors.lastname: Czeczko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000473:pathology / Q000601:surgery; D018450:Disease Progression; D005260:Female; D006801:Humans; D053554:Keratin-20 / Q000096:biosynthesis*; D019394:Ki-67 Antigen / Q000096:biosynthesis*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D011379:Prognosis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis*; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000601:surgery
chemical_list: D053554:Keratin-20; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53